About Us
Biopsomic AG is a Swiss MedTech company pioneering a breakthrough in early cancer detection by decoding small extracellular vesicle (sEV) based proteomics. Our innovative technology (R&D stage) is designed to identify metastatic risk during early stage cancers, weeks or months earlier than current methods. Unlocking the critical window in which the majority of solid tumours remain localised and curative-intent treatment (surgery ± adjuvant therapy) provides five-year overall survival rates of 70–90 %.
The Challenge
Metastasis causes nearly 90% of cancer deaths. Current diagnostics often miss early metastatic signals from live cells, delaying intervention until it's too late for effective treatment.
Our Solution
Our low-cost, fully automated sEV assay detects live mesenchymal-cell activity weeks to months earlier than current methods. This provides critical early signals for high-risk patients and accurate minimal residual disease detection faster.
Clinical Impact
Projected 92-97% sensitivity and 96-98% specificity across stages I-IV + MRD in NSCLC and CRC, with <8 hour turnaround and significantly lower costs than current genomic alternatives.
The Science Behind Our Technology
Why sEVs Excel Over ctDNA
Small extracellular vesicles (sEVs) offer a fundamentally different window into metastatic progression. Rather than detecting genetic material from dying cells, our approach captures dynamic phenotypic changes from live, actively metastasising cancer cells through epithelial-mesenchymal transition (EMT) protein signatures.
1
Early Detection
Captures EMT phenotypic changes months before genomic signals appear, enabling intervention during the subclinical window when treatment is most effective.
2
Superior Stability
Abundant, stable biomarkers (10⁹-10¹² particles/mL) protected by double-membrane structure, providing reliable detection with minimal degradation throughout processing.
3
Unique Edge: Longitudinal Phenotypic Tracking
Building on ctDNA's serial genomic monitoring, Biopsomic's sEV tests aim to establish patient-specific baselines from living cell protein signals, independently of tumor burden. This enables dynamic tracking of EMT for evolving, personalized metastatic risk profiles – empowering proactive therapy guidance in a multi-omics era.
Clinically Validated Performance
Published proof-of-concept study (Nature, 2023) in 100 non-small cell lung cancer (NSCLC) patients (Stage I-IIIA) demonstrating exceptional predictive power.
Get In Touch
Grow with us…
Interested in learning more?
We welcome enquiries about our technology, investment opportunities, clinical collaborations, and partnership possibilities. Our team is ready to discuss how Biopsomic's innovative sEV proteomics platform can transform early cancer detection and improve patient outcomes.
© 2025 Biopsomic AG | All rights reserved | New Frontiers Diagnostics